Table S1. Summary of clinical signs and RNAemia in groups of mice mock immunised with PBS, or immunised with rVP2 or rVP5 of different serotypes, then challenged with BTV belonging to homologous or heterologous serotypes

Group (immunogen / challenge virus)	Day 4-Day 5	Day 7	Day 12
Group1 (mock / BTV-1RG _{C7})	Mild Clinical signs, all mice alive CT= 22.17; 21.53; 24.10; 22.85; 21.87, Mean= 22.7	Mild Clinical signs, all mice alive: CT= 28.12; 27.08; 29 25.83; 29.47, Mean= 28.01	.55; All mice recovered: CT= 39.34; 38.15; 37.06; 39.14; 38.66, Mean= 38.47
Group2 (mock / BTV-4RSArrrr/04 control)	Severe clinical signs (day 4), all mice died on day 4: CT=20.63; 21.67; 22.21; 23.41; 22.64, Mean=22.11		
Group3 (mock / BTV-8RSArrrr/08 control)	Severe clinical signs (day 4), 4 mice died on day 4 and or died on day 5 CT= 22.45; 21.27; 23.45; 23.11; 21.64, Mean= 22.38	ne	
Group4 (VP2 BTV-1 / BTV-1RGc7) Group5 (VP2 BTV-1 / BTV-4RSArrrr/04)	No clinical signs, all mice alive CT=26.91; 28.37; 26.82; 29.73; 27.10, Mean= 27.78 Severe clinical signs (day 4), All mice died on day 4 CT=21.63; 22.84; 24.13; 23.77; 24.75, Mean= 23.42	No clinical signs, all mice alive: CT= 29.47; 29.9; 29 30.65; 30.01, Mean= 29.87	.24;All mice alive : CT= 39.61; 38.45; 39.26; 37.94; 40.12, Mean= 39.07
Group6 (VP2 BTV-1 / BTV-8RSArrrr/08)	Severe clinical signs (day 4), all mice died day 4 CT=23.97; 23.84; 21.61; 22.47; 24.98, Mean= 23.37		
Group7 (VP2 BTV-4 / BTV-1RG _{C7})	Severe clinical signs (day4-day5), one mouse died on da 4 and 4 mice died on day 5 CT=20.42; 19. 47; 20.98; 20.59; 18.61, Mean= 20.01	ay	
Group8 (VP2 BTV-4 / BTV-4RSArrrr/04) Group9 (VP2 BTV-4 / BTV-8RSArrrr/08)	No clinical signs all alive CT=26.43; 27.61; 27.73; 30.13; 28.64, Mean= 28.10 Severe clinical signs, all mice died on day 4 CT=22.13; 20.86; 20.41; 21.35; 20.72, Mean=	No clinical signs, all mice alive: CT= 30.85; 30.37; 34 33.44; 35.31, Mean= 32.95	.79;All mice alive: CT= 37.10; 36.67; 38.06; 40.72; 39.09, Mean= 37.72
Group10 (VP2 BTV-8 / BTV-1RGc7)	Mild/severe clinical signs (day 4-day 5), all mice died da 5: CT= 18.52; 20.55; 21.69; 19.38; 20.69, Mean= 20.16	ay	
Group11 (VP2 BTV-8 / BTV-4RSArrrr/04) Group12	Severe clinical signs (day 4), all mice died day 4 CT=23.98; 21.17; 22.06; 23.11 21.53, Mean= 22.37 Mild Clinical signs, all mice alive	No clinical signs, all mice alive: CT=33.68; 34.12; 35	
(VP2 BTV-8 / BTV-8RSArrrr/08)	CT =29.84; 28.29; 30.01; 27.64; 27.12, Mean = 28.6	32.19; 31.09, Mean = 33.32	40.10; 39.82; 40.12, Mean= 39.83
Group13	Mild/sever clinical signs (day 5)	Severe clinical signs, all mice died day 7: CT=19.62; 21	.01;
(VP5 BTV-10 / BTV-1RG _{C7})	CT =19.97; 20.7; 19.57; 21.35; 19.26, Mean = 20.17 Severe elipical sizes (day 4) all mice diad on day 4. CT =22.5	18.91; 20.40; 19.56, Mean= 19.9	
Group14 (VP5 BTV-10 / BTV-4RSArrrr/04)	Severe clinical signs (day 4), all mice died on day 4. CT= 22.5 22.40; 23.99; 21.71; 21.94, Mean= 22.51	З,	
Group15	Severe clinical signs (day 4), all mice died on day 4		
(VP5 BTV-10 / BTV-8RSArrrr/08)	CT =20.10; 23.05; 24.1; 21.14; 22.56, Mean = 22.19		

Observed severe clinical signs	
Scruffy fur	
Profuse lacrimation	
Eye lids permanently shut	
Sticky secretions from the eyes	
Prostration	
Dehydration	

Table S2: Observed mild or severe clinical signs in IFNAR^(-/-) mice infected with BTV.

The mice that developed mild clinical signs, recovered and survived, while mice that developed severe clinical signs had all died by day 4 to 7 post challenge.

Table S3: The statistical significance of differences in the real-time RT-PCR results between groups of mice challenged with BTV-4RSArrrr/04.

Compared groups	Tukey HSD calculated p-value	Significance
Gp2 / Gp5	0.3997127	N.S.
Gp2 / Gp8	0.0010053	** p<0.01
Gp2 / Gp11	0.8999947	N.S.
Gp2 / Gp14	0.8999947	N.S.
Gp5 / Gp8	0.0010053	** p<0.01
Gp5 / Gp11	0.5937424	N.S.
Gp5 / Gp14	0.7005442	N.S.
Gp8 / Gp11	0.0010053	** p<0.01
Gp8 / Gp14	0.0010053	** p<0.01
Gp11 / Gp14	0.8999947	N.S.

Analysis of variance (ANOVA) using Tukey's test with HSD for the real-time RT-PCR Ct values of RNA extract from blood samples collected on day 4-5 post-challenge with BTV-4RSArrrr/04. **N.S.:** not significant

Gp2: mock-immunised

Gp5: immunised with VP2 BTV-1

Gp8: immunised with VP2 BTV-4

Gp11: immunised with VP2 BTV-8

Gp14: immunised with VP5 BTV-10

Table S4: The statistical significance of differences in the real-time RT-PCR results between groups of mice challenged with BTV-8RSArrrr/08.

Compared groups	Tukey HSD calculated p-value	Significance
Gp3 / Gp6	0.6753846	N.S.
Gp3 / Gp9	0.4620797	N.S.
Gp3 / Gp 12	0.0010053	** p<0.01
Gp3 / Gp15	0.8999947	N.S.
Gp6 / Gp9	0.0502538	N.S.
Gp6 / Gp12	0.0010053	** p<0.01
Gp6 / Gp15	0.5381951	N.S.
Gp9 / Gp12	0.0010053	** p<0.01
Gp9 / Gp15	0.6004254	N.S.
Gp12 / Gp15	0.0010053	** p<0.01

Analysis of variance (ANOVA) using Tukey's test with HSD for the real-time RT-PCR Ct values of RNA extract from blood samples collected on day 4-5 post-challenge with BTV-8RSArrrr/08. **N.S:** not significant

Gp3: mock-immunised

Gp6: immunised with VP2 BTV-1

Gp9: immunised withVP2 BTV-4

Gp12: immunised with VP2 BTV-8

Gp15: immunised with VP5 BTV-10

Table S5: The statistical significance of differences in the real-time RT-PCR results between groups of mice challenged with BTV-1RGc7.

Compared groups	Tukey HSD calculated p-value	Significance
Gp1 / Gp4	0.0010053	** p<0.01
Gp1 / Gp7	0.0119114	* p<0.05
Gp1 / Gp10	0.0194239	* p<0.05
Gp1 / Gp13	0.0196736	* p<0.05
Gp1 / Gp13*	0.0065790	** p<0.01
GP4 / Gp7	0.0010053	** p<0.01
Gp4 / Gp10	0.0010053	** p<0.01
Gp4 / Gp13	0.0010053	** p<0.01
Gp4 / Gp13*	0.0010053	** p<0.01
Gp7 / Gp10	0.8999947	N.S.
Gp7 / Gp13	0.8999947	N.S.
Gp7 / Gp13*	0.8999947	N.S.
Gp10 / Gp13	0.8999947	N.S.
Gp13 / Gp13*	0.8999947	N.S.

Analysis of variance (ANOVA) using Tukey's test with HSD for the real-time RT-PCR Ct values of RNA extract from blood samples collected on day 4-5 post-challenge with BTV-1RGC7.

* samples collected on day 7 from mice of group 13 before they died. N.S: not significant

Gp1: mock-immunised

Gp4: immunised with VP2 BTV-1

Gp7: immunised with VP2 BTV-4

Gp10: immunised with VP2 BTV-8

Gp13: immunised with VP5 BTV-10